ReviewFrontiers in medicine2026
Beyond blood gases: diaphragm-guided sequential non-invasive ventilation for COPD with type II respiratory failure.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) with type II respiratory failure is driven by diaphragm load-capacity imbalance and abnormal central respiratory drive, yet clinical decision-making for sequential non-invasive ventilation (NIV) remains largely dependent on blood gas normalization. This narrative review, informed by a structured literature search of PubMed, Embase, and Cochrane Library (January 2000 to June 2026), synthesizes physiological evidence supporting a shift from blood gas-guided to diaphragm-guided sequential NIV management. We propose a testable, three-tier conceptual framework stratified by bedside-measured diaphragmatic thickening fraction (DTF): patients with DTF below 20% may experience severe diaphragmatic impairment requiring sustained high-intensity spontaneous/timed ventilation; those with DTF between 20 and 30% likely retain limited reserve suited to adaptive average volume-assured pressure support as a transitional bridge; and patients with DTF above 30% presumably possess sufficient muscle recovery to transition to proportional assist ventilation or neurally adjusted ventilatory assist for diaphragmatic conditioning. These DTF cutoffs and corresponding mode allocations are provisional hypotheses extrapolated from acute NIV and ICU weaning cohorts and require prospective multicenter validation before routine clinical use. This work addresses three key evidence gaps: longitudinal peri-transition DTF trajectories, ventilation mode comparisons with diaphragmatic functional endpoints, and unconfirmed stratification thresholds, with dedicated prospective trial designs proposed accordingly. Importantly, conventional blood gas assessment remains the validated core standard of care, and this DTF-based strategy only serves as an adjunct physiological tool. Combined serial diaphragmatic ultrasound and respiratory drive monitoring shifts clinical focus from passive biochemical correction to comprehensive physiological recovery, delivering an individualized, physiology-centered strategy to mitigate ventilatory transition failure in advanced COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.